Rhythm Pharmaceuticals Inc
$ 86.81
2.87%
13 Apr - close price
- Market Cap 5,762,574,000 USD
- Current Price $ 86.81
- High / Low $ 87.61 / 83.96
- Stock P/E N/A
- Book Value 2.07
- EPS -3.11
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.90 %
- 52 Week High 122.20
- 52 Week Low 55.31
About
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$137.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-02-20 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 | 2023-08-01 | 2023-05-02 |
| Reported EPS | -0.73 | -0.82 | -0.75 | -0.81 | -0.72 | -0.73 | -0.69 | -2.35 | -0.7 | -0.76 | -0.82 | -0.92 |
| Estimated EPS | -0.8218 | -0.71 | -0.67 | -2.16 | -0.73 | -0.8 | -0.71 | -2.16 | -0.7 | -0.74 | -0.79 | -0.73 |
| Surprise | 0.0918 | -0.11 | -0.08 | 1.35 | 0.01 | 0.07 | 0.02 | -0.19 | 0 | -0.02 | -0.03 | -0.19 |
| Surprise Percentage | 11.1706% | -15.493% | -11.9403% | 62.5% | 1.3699% | 8.75% | 2.8169% | -8.7963% | 0% | -2.7027% | -3.7975% | -26.0274% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.84 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RYTM
2026-04-13 01:39:28
Rhythm Pharmaceuticals (RYTM) has experienced a recent share price pullback, declining 19.5% over the past three months, despite a 41.7% return over one year. The article assesses RYTM's valuation, noting it trades at a significant discount to analyst price targets and an estimated intrinsic value of $137.27, primarily due to upcoming potential regulatory approvals and intellectual property protection for its lead asset. However, it also highlights valuation risks, including the company's high P/S ratio of 30.4x compared to a peer average of 6.9x, and advises investors to consider these factors alongside future growth expectations.
2026-04-12 10:09:57
Rhythm Pharmaceuticals (RYTM) has seen a significant 48.9% share price gain over the past year. A Discounted Cash Flow (DCF) analysis suggests the stock is 79.8% undervalued, estimating an intrinsic value of $426.55 per share against its current price of US$86.13. However, its Price-to-Sales (P/S) ratio of 30.99x is above the industry average, indicating it might be overvalued based on revenue multiples compared to peers.
2026-04-10 21:39:45
Rhythm Pharmaceuticals (RYTM) stock has seen significant gains over the past year, attracting investor interest due to its focus on rare genetic disorders and clinical pipeline. While a Discounted Cash Flow analysis suggests the stock is significantly undervalued, its Price/Sales ratio indicates it trades at a richer multiple than industry peers. Simply Wall St provides tools for investors to create their own valuation narratives based on differing assumptions.
2026-04-10 08:38:53
Rhythm Pharmaceuticals, Inc. announced it will release its first-quarter 2026 financial results on Tuesday, May 5, 2026, via a live conference call and webcast. Additionally, CFO Hunter Smith will participate in the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. The company also provided detailed information about its lead asset, IMCIVREE (setmelanotide), including its indications, limitations of use, and important safety information.
2026-04-09 12:10:15
Rhythm Pharmaceuticals will host a conference call and webcast on Tuesday, May 5, 2026, at 8 a.m. ET to announce its first quarter 2026 financial results and provide a corporate update. Additionally, CFO Hunter Smith will participate in the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026, at 11:00 a.m. ET. Webcasts for both events will be available on the company's investor relations website.
2026-04-08 05:39:28
Rhythm Pharmaceuticals (RYTM) recently saw a 12.6% stock increase following a positive opinion from the European Medicines Agency's CHMP to expand IMCIVREE's authorization for acquired hypothalamic obesity and the appointment of Kim Popovits to its Board. This dual development is expected to significantly impact Rhythm's focus on rare neuroendocrine diseases. While the EU expansion and new board member could bolster the company's investment narrative, investors are cautioned about ongoing operating losses and potential dilutive equity issuance, especially given the recent US$200 million at-the-market offering.
